Logo

Biocept's Immuno-Oncology PD-L1 Test

May 31, 2016

Biocept has launched its first test for use in guiding cancer immunotherapies, a PD-L1 protein expression assay performed on circulating tumor cells. The CLIA-validated test, developed by Biocept scientists in collaboration with Yale University School of Medicine's David Rimm, is intended to be used to detect and monitor PD-L1 protein expression throughout the course of a patient's treatment with newly approved immuno-oncologic drugs.  

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.